Catalyst struck a deal Wednesday with Teva that will prevent the generic drugmaker from knocking off Firdapse until 2035.

"Vantage and TotalEnergies form TEVA JV to acquire Tungsten Explorer" was originally created and published by Offshore ...

Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) entered into a settlement agreement with Teva Pharmaceuticals Industries Ltd ...

Despite weathering significant criticism from lawmakers and patient groups over the steep cost of its rare disease med ...

BofA keeps a Buy rating on Catalyst Pharmaceuticals (CPRX) with a $30 price target following the announcement of a Firdapse patent settlement ...

Teva Pharmaceutical Industries Ltd (TEVA) stock saw a decline, ending the day at $21.49 which represents a decrease of $-0.11 or -0.51% from the prior close of $21.6. The stock opened at $21.59 and ...

In its survey of the Internet sector, Cantor Fitzgerald selected Wix, led by CEO Avishai Abrahami, as a top pick, along with ...

Two Israeli stocks have been included in the top picks 2025 lists of US analysts. Bank of America chose Teva Pharmaceutical ...

After reinvigorating a decades-old schizophrenia drug in an innovative long-acting treatment option, Teva is looking to ...

Teva Pharmaceutical Industries continues to impress investors with strong sales growth and promising development. Click here ...

Catalyst Pharmaceuticals (CPRX) announced that the company and its licensor SERB S.A. have entered into a Settlement Agreement with Teva ...

Technical analysis for Teva Pharmaceutical Industries Limited American Depositary Shares TEVA including support levels ...